Although localized prostate cancer may be successfully treated with radical prostatectomy or radiotherapy [3], standard androgen deprivation therapy (ADT) followed by chemotherapy (Taxanes), androgen synthesis inhibitor (abiraterone), or androgen receptor (AR) antagonists (enzalutamide, apalutamide, and darolutamide) remains the primary treatment option for patients with advanced prostate cancer [4]. This evidence concerns the gene AR and prostate carcinoma.